Published in N Engl J Med on October 31, 2013
Preventing Sexual Transmission of HIV With Anti-HIV Drugs | NCT00074581
Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV Treatment as Prevention" experience in a Canadian setting. PLoS One (2014) 2.20
Cost-effectiveness of the Three I's for HIV/TB and ART to prevent TB among people living with HIV. Int J Tuberc Lung Dis (2014) 1.46
Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection. J Infect Dis (2015) 1.45
Rapid urine-based screening for tuberculosis to reduce AIDS-related mortality in hospitalized patients in Africa (the STAMP trial): study protocol for a randomised controlled trial. BMC Infect Dis (2016) 1.42
Addressing the Achilles' heel in the HIV care continuum for the success of a test-and-treat strategy to achieve an AIDS-free generation. Clin Infect Dis (2014) 1.17
HCV and HIV co-infection: mechanisms and management. Nat Rev Gastroenterol Hepatol (2014) 1.16
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2014) 1.09
Attrition through multiple stages of pre-treatment and ART HIV care in South Africa. PLoS One (2014) 1.06
Process monitoring of an HIV treatment as prevention program in British Columbia, Canada. J Acquir Immune Defic Syndr (2014) 0.96
Global response to HIV: treatment as prevention, or treatment for treatment? Clin Infect Dis (2014) 0.94
Tracking development assistance for HIV/AIDS: the international response to a global epidemic. AIDS (2016) 0.91
Cost effectiveness of 'on demand' HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in Canada. Can J Infect Dis Med Microbiol (2015) 0.90
The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. Br J Clin Pharmacol (2015) 0.88
Economic and epidemiological impact of early antiretroviral therapy initiation in India. J Int AIDS Soc (2015) 0.88
HIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials. AIDS Res Hum Retroviruses (2015) 0.87
Dynamic Transmission Economic Evaluation of Infectious Disease Interventions in Low- and Middle-Income Countries: A Systematic Literature Review. Health Econ (2016) 0.85
Point-of-care CD4 testing to inform selection of antiretroviral medications in south african antenatal clinics: a cost-effectiveness analysis. PLoS One (2015) 0.85
Modeling the implementation of universal coverage for HIV treatment as prevention and its impact on the HIV epidemic. Curr HIV/AIDS Rep (2014) 0.85
Performance of a mathematical model to forecast lives saved from HIV treatment expansion in resource-limited settings. Med Decis Making (2014) 0.83
Should HIV testing for all pregnant women continue? Cost-effectiveness of universal antenatal testing compared to focused approaches across high to very low HIV prevalence settings. J Int AIDS Soc (2016) 0.82
Public health impact and cost-effectiveness of dairy products supplemented with vitamin D in prevention of osteoporotic fractures. Arch Public Health (2015) 0.81
Cost-effectiveness of antivenoms for snakebite envenoming in Nigeria. PLoS Negl Trop Dis (2015) 0.81
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2014) 0.80
Supporting HIV prevention and reproductive goals in an HIV-endemic setting: taking safer conception services from policy to practice in South Africa. J Int AIDS Soc (2017) 0.79
Modeling and Cost-Effectiveness in HIV Prevention. Curr HIV/AIDS Rep (2016) 0.79
Treatment as prevention--where next? Curr HIV/AIDS Rep (2014) 0.78
The Anticipated Clinical and Economic Effects of 90-90-90 in South Africa. Ann Intern Med (2016) 0.78
The impact of the 2013 WHO antiretroviral therapy guidelines on the feasibility of HIV population prevention trials. HIV Clin Trials (2014) 0.77
Newborn screening and prophylactic interventions for sickle cell disease in 47 countries in sub-Saharan Africa: a cost-effectiveness analysis. BMC Health Serv Res (2016) 0.77
Cost-Effectiveness of Antivenoms for Snakebite Envenoming in 16 Countries in West Africa. PLoS Negl Trop Dis (2016) 0.76
The HIV Cure Research Agenda: The Role of Mathematical Modelling and Cost-Effectiveness Analysis. J Virus Erad (2015) 0.75
Antiretroviral therapy: when to start. Infect Dis Clin North Am (2014) 0.75
Highlights of the International Congress on Drug Therapy in HIV Infection, 23-26 October 2016, Glasgow, UK. J Virus Erad (2017) 0.75
Improving on effective antiretroviral therapy: how good will a cure have to be? J Med Ethics (2016) 0.75
HIV prevention & treatment - Reasons to rejoice & remain vigilant. Indian J Med Res (2015) 0.75
Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies. Clin Infect Dis (2016) 0.75
EPICE-HIV: An Epidemiologic Cost-Effectiveness Model for HIV Treatment. PLoS One (2016) 0.75
Survival benefits of antiretroviral therapy in Brazil: a model-based analysis. J Int AIDS Soc (2016) 0.75
Expanding human immunodeficiency virus testing and counseling to reach tuberculosis clients' partners and families. Int J Tuberc Lung Dis (2015) 0.75
Setting Performance Standards for a Cost-Effective Human Immunodeficiency Virus Cure Strategy in South Africa. Open Forum Infect Dis (2017) 0.75
Differences in health-related quality of life between HIV-positive and HIV-negative people in Zambia and South Africa: a cross-sectional baseline survey of the HPTN 071 (PopART) trial. Lancet Glob Health (2017) 0.75
Betting on the fastest horse: Using computer simulation to design a combination HIV intervention for future projects in Maharashtra, India. PLoS One (2017) 0.75
Antiretroviral therapy initiation in an Australian cohort: implications for increased use of antiretroviral therapy. Eur J Clin Microbiol Infect Dis (2014) 0.75
The value of point-of-care CD4+ and laboratory viral load in tailoring antiretroviral therapy monitoring strategies to resource limitations. AIDS (2017) 0.75
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med (2007) 19.78
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet (2010) 16.90
Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet (2001) 13.32
Towards an improved investment approach for an effective response to HIV/AIDS. Lancet (2011) 11.89
Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS (2009) 11.62
Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health (2010) 8.81
Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One (2009) 8.58
HIV-1 transmission, by stage of infection. J Infect Dis (2008) 6.57
The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet (2011) 5.87
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med (2011) 5.35
Effectiveness of antiretroviral treatment in a South African program: a cohort study. Arch Intern Med (2008) 5.17
Who infects whom? HIV-1 concordance and discordance among migrant and non-migrant couples in South Africa. AIDS (2003) 4.87
Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis (2010) 4.41
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78
Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr (2009) 3.41
CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr (2006) 3.39
Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters. Arch Intern Med (2011) 2.99
Scaling up antiretroviral therapy in South Africa: the impact of speed on survival. J Infect Dis (2008) 2.96
Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS (2005) 2.39
Scaling up the 2010 World Health Organization HIV Treatment Guidelines in resource-limited settings: a model-based analysis. PLoS Med (2010) 2.10
Estimating HIV prevalence and risk behaviors among high-risk heterosexual men with multiple sex partners: use of respondent-driven sampling. J Acquir Immune Defic Syndr (2009) 1.23
Usefulness of an observational database to assess antiretroviral treatment trends in India. Natl Med J India (2006) 1.10
HIV treatment produces economic returns through increased work and education, and warrants continued US support. Health Aff (Millwood) (2012) 1.00
Overview of pharmacoeconomic modelling methods. Br J Clin Pharmacol (2013) 0.84
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet (2006) 31.79
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med (2015) 15.06
Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS (2008) 13.25
Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS (2005) 11.25
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis (2005) 10.20
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis (2006) 9.25
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Expanded screening for HIV in the United States--an analysis of cost-effectiveness. N Engl J Med (2005) 8.49
Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30
Detection of acute infections during HIV testing in North Carolina. N Engl J Med (2005) 7.60
Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis (2011) 7.23
Long-term persistence in use of statin therapy in elderly patients. JAMA (2002) 7.19
The survival benefits of AIDS treatment in the United States. J Infect Dis (2006) 7.08
The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol (2004) 7.04
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis (2009) 6.96
Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS (2005) 6.83
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med (2011) 6.79
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis (2008) 6.73
Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet (2002) 6.54
Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med (2011) 6.42
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29
Rapid scale-up of a community-based HIV treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S Afr Med J (2006) 6.29
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
Surgery versus physical therapy for a meniscal tear and osteoarthritis. N Engl J Med (2013) 6.08
Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet (2010) 6.02
The lifetime cost of current human immunodeficiency virus care in the United States. Med Care (2006) 5.87
The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet (2011) 5.87
Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis (2008) 5.85
Syphilis in China: results of a national surveillance programme. Lancet (2007) 5.76
Impact of HIV infection on the epidemiology of tuberculosis in a peri-urban community in South Africa: the need for age-specific interventions. Clin Infect Dis (2006) 5.68
Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA (2004) 5.66
Natural variation in Ghd7 is an important regulator of heading date and yield potential in rice. Nat Genet (2008) 5.64
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
The draft genome of the transgenic tropical fruit tree papaya (Carica papaya Linnaeus). Nature (2008) 5.54
Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med (2006) 5.53
Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS (2003) 5.52
Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr (2009) 5.48
Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS (2007) 5.41
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet (2010) 5.41
Population-based study of chlamydial infection in China: a hidden epidemic. JAMA (2003) 5.40
Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr (2009) 5.40
Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet (2011) 5.34
Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis (2007) 5.32
Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis (2008) 5.14
Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann Intern Med (2008) 5.13
Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med (2011) 5.06
Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis (2005) 4.96
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS (2007) 4.89
HIV/AIDS risk among brothel-based female sex workers in China: assessing the terms, content, and knowledge of sex work. Sex Transm Dis (2004) 4.88
Does preventive care save money? Health economics and the presidential candidates. N Engl J Med (2008) 4.78
The "ART" of linkage: pre-treatment loss to care after HIV diagnosis at two PEPFAR sites in Durban, South Africa. PLoS One (2010) 4.75
Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS (2010) 4.68
Bipolar transurethral resection of the prostate causes deeper coagulation depth and less bleeding than monopolar transurethral prostatectomy. Urology (2012) 4.61
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest (2005) 4.55
Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One (2009) 4.52
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med (2013) 4.43
Association between hospital and surgeon procedure volume and the outcomes of total knee replacement. J Bone Joint Surg Am (2004) 4.42
Rates and outcomes of primary and revision total hip replacement in the United States medicare population. J Bone Joint Surg Am (2003) 4.38
When to start antiretroviral therapy in resource-limited settings. Ann Intern Med (2009) 4.31
Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ Res (2003) 4.29
Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med (2011) 4.29